{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
vitamin a
to a specific field?
Status:
Investigational
Source:
NCT00248183: Phase 3 Interventional Completed Anxiety Disorders
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Naluzotan (PRX-00023), a small molecule, non-azapirone, dual serotonin (5-HT)1A receptor agonist and sigma-1 receptor antagonist, is under development with Proximagen for the treatment of epilepsy. In previous clinical trials, the compound was shown to be safe and well-tolerated in over 400 patients. Epilepsy patients with localisation-related epilepsy have reduced 5-HT1a receptor binding as indicated by positron emission tomography (PET scan). It is thought that by increasing neurotransmitter activity at 5-HT1a receptor sites, seizure incidence and severity may be decreased.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Ralitoline is thiazolidinylidene derivative patented by Goedecke A.-G. as an anticonvulsant. In preclinical models, ralitoline blocks sustained repetitive firing of sodium action potentials with effects on firing activity triggered by spontaneous excitatory postsynaptic potentials at higher concentrations. No effects on iontophoretic GABA and glutamate responses were noted. Ralitoline inhibit the binding of tritiated batrachotoxinin A 20-alpha-benzoate ([3H]BTX-b) to rat brain synaptosomes. In healthy volunteers with single and multiple doses (50-200 mg). ralitoline is well absorbed by oral ingestion, with peak plasma concentrations occurring approximately 2-3 hr postdose. Approximately 2 weeks of administration of ralitoline had no effect on the steady-state kinetics of phenytoin or phenobarbitone in healthy volunteers.
Status:
Investigational
Source:
NCT00442780: Phase 2 Interventional Completed Parkinson's Disease
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Vipadenant (V2006) is a small molecule, adenosine A2A receptor antagonist that was being investigated in Parkinson's disease. Due to safety concerns development ceased in 2010 and the rights were regained from Biogen Idec in 2011 with no further investment made. In October 2014, RedoxTherapies licensed Vipadenant as it has the potential to disrupt an immunosuppressive mechanism of tumour protection, generating improved efficacy for immunotherapies of certain cancers when used in combination with other drugs.
Status:
Investigational
Source:
NCT04155515: Phase 3 Interventional Completed Chronic Hepatics C Virus (HCV) Genotype 1
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Furaprevir (also known as TG-2349), an NS3/4A protease inhibitor, discovered and developed by TaiGen for the treatment of chronic hepatitis C. Furaprevir blocks the protease enzyme that is essential in hepatitis C virus replication. In April 2019, TaiGen started the Phase III trial of the combination therapy Furaprevir - Yimitasvir for the treatment of chronic hepatitis C patients.
Class (Stereo):
CHEMICAL (ACHIRAL)
Necopidem, a zolpidem derivative, is an anxiolytic and sedative drug.
Status:
Investigational
Source:
NCT03022799: Phase 1 Interventional Completed Parkinson's Disease
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01429623: Phase 2 Interventional Completed Mild Cognitive Impairment
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
LADOSTIGIL, a rasagiline derivative, is a reversible acetylcholinesterase and butyrylcholinesterase inhibitor with neuroprotective properties. It also acts as an irreversible brain monoamine oxidases inhibitor. It is under development for the treatment of neurodegenerative disorders like dementia and Alzheimer's disease.
Status:
Investigational
Source:
NCT03348527: Phase 2 Interventional Completed Prostate Cancer
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Hydroxyflutamide is the major active metabolite of flutamide. Flutamide undergoes extensive first-pass metabolism by CYP1A2 to its metabolite hydroxyflutamide and its hydrolysis product, 3-trifluoromethyl-4-nitroaniline. Hydroxyflutamide is a more powerful antiandrogen in vivo, with higher affinity for the receptor than that of flutamide. Hydroxyflutamide is in phase II clinical trials for the treatment of prostate cancer. However, a drug resistance problem appears after about one year's treatment. Per-residue free energy decomposition analyses indicate that N705, T877, and M895 androgen receptor mutations are vital residues in the agonist/antagonist mechanism of hydroxyflutamide.
Status:
Investigational
Source:
INN:vanitiolide [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Vanitiolide is a choleretic agent.
